These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 9290539)

  • 1. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions.
    Dagogo-Jack S; Santiago JV
    Arch Intern Med; 1997 Sep; 157(16):1802-17. PubMed ID: 9290539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promising new approaches.
    Reasner CA
    Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy for type 2 diabetes mellitus.
    Elson DF; Meredith M
    WMJ; 1998 Mar; 97(3):49-54. PubMed ID: 9540451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings.
    Collins FM
    Am J Manag Care; 2002 Oct; 8(16 Suppl):S460-71. PubMed ID: 12408409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
    DeFronzo RA
    Am J Med; 2010 Mar; 123(3 Suppl):S38-48. PubMed ID: 20206731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities.
    Resmini E; Minuto F; Colao A; Ferone D
    Acta Diabetol; 2009 Jun; 46(2):85-95. PubMed ID: 19322513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Postprandial blood glucose as the driving force in pathogenesis of type 2 diabetes].
    Liebl A
    Med Klin (Munich); 2003 Oct; 98 Suppl 1():7-11. PubMed ID: 14694835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of pancreatic beta-cells: is it feasible?
    Bonora E
    Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acarbose is a promising therapeutic strategy for the treatment of patients with nonalcoholic steatohepatitis (NASH).
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(2):377-9. PubMed ID: 15922116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-insulin-dependent (type II) diabetes mellitus.
    Rodger W
    CMAJ; 1991 Dec; 145(12):1571-81. PubMed ID: 1742694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fate of the beta-cell in the pathophysiology of type 2 diabetes.
    Campbell RK
    J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S10-5. PubMed ID: 19801360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin resistance and its impact on the approach to therapy of type 2 diabetes.
    Laakso M
    Int J Clin Pract Suppl; 2001 Sep; (121):8-12. PubMed ID: 11594246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of thiazolidinediones in the management of type 2 diabetes: focus on ethnic minority populations.
    Umpierrez G; Dagogo-Jack S
    Ethn Dis; 2006; 16(1):51-7. PubMed ID: 16599348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2 diabetes: stepped-care approach to patient management.
    McFarland KF
    Geriatrics; 1997 Oct; 52(10):22-6, 35, 39. PubMed ID: 9337803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral combination therapy with thiazolidinediones in type 2 diabetes.
    LaSalle JR; Cross LB
    Am J Manag Care; 2006 Nov; 12(14 Suppl):S369-81. PubMed ID: 17112324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of beta-cell management in type 2 diabetes.
    Standl E
    Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time to insulin in type-2 diabetes: high hurdles or Santiago way?
    Rotella CM; Pala L
    Acta Diabetol; 2008 Jun; 45(2):67-74. PubMed ID: 18408882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the pharmacotherapeutic options for treating type 2 diabetes.
    Kruger DF
    Diabetes Educ; 2008; 34 Suppl 3():60S-65S. PubMed ID: 18525066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple drug targets in the management of type 2 diabetes.
    Moneva MH; Dagogo-Jack S
    Curr Drug Targets; 2002 Jun; 3(3):203-21. PubMed ID: 12041735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.